Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Anika Therapeutics (NASDAQ:ANIK) and raised the price target from $29 to $37.
March 14, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anika Therapeutics' Outperform rating is maintained by Barrington Research, with a raised price target from $29 to $37.
The maintenance of an Outperform rating combined with an increased price target typically signals a strong bullish sentiment from the analyst. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100